KRAS and BRAF mutational status in colon cancer from Albanian patients by Daniela Martinetti et al.
Martinetti et al. Diagnostic Pathology 2014, 9:187
http://www.diagnosticpathology.org/content/9/1/187RESEARCH Open AccessKRAS and BRAF mutational status in colon cancer
from Albanian patients
Daniela Martinetti1, Rosario Costanzo1, Shahin Kadare2, Mehdiu Alimehmeti3, Cristina Colarossi4,
Vincenzo Canzonieri5, Massimiliano Berretta6 and Lorenzo Memeo1,4*Abstract
Background: Numerous clinical studies have shown that anti-EGFR therapies are effective only in a subset of patients
with colorectal cancer. Mutations in the KRAS and BRAF genes have been confirmed as negative predictors of the
response to EGFR-targeted therapies.
In this study we evaluated KRAS and BRAF status in 159 colorectal cancer samples obtained from the University of
Tirana.
Methods: We evaluated KRAS mutations in codons 12, 13, 61, 146 and in codon 600 of BRAF by direct sequencing.
90 patients were male (57%) and 69 female (43%); the patients’ ages ranged from 17 to 85 (median 61.7). 24 patient
were stage I, 36 stage II, 84 stage III and 15 stage IV.
Results: Out of the 159 cases, 28 (17,6%) showed KRAS mutation (13 G12D, 4 G12C, 4 G12V, 3 G12A, 2 G13 D, 1 G12S
and 1 A146T), and 10 (6,3%) showed BRAF mutation (all V600E). No significant correlations between KRAS and BRAF
mutations and various clinicopathological parameters was found.
This is the first report of KRAS and BRAF status in Albanian patients with colorectal carcinoma (CRC) and though the
relatively small sample size might not provide enough statistics power.
Conclusions: The results of KRAS and BRAF mutation analysis could be used in the selection of patients for anti-EGFR
therapy.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_187
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Colorectal cancer (CRC) is the third most common ma-
lignancy in men and women with an incidence of
1,234,000 cases contributing 10% of the total burden [1].
The incidence rates of colon cancer vary in various
geographic locations with highest rates estimated in
Australia/New Zealand and Western Europe [2].
The development of CRC is a multistep process that
occurs because of the accumulation of several genetic
alterations, including chromosomal abnormalities, gene
mutations, and epigenetic modifications involving several* Correspondence: lorenzo.memeo@grupposamed.com
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unless otherwise stated.genes that regulate proliferation, differentiation, apoptosis,
and angiogenesis [3,4].
Of the various genetic alterations, an important mo-
lecular target for metastatic CRC treatment is the epi-
dermal growth factor receptor (EGFR). EGFR, a tyrosine
kinase receptor belonging to the ErbB family, has been
found to play a significant role in the pathogenesis of
CRC by inducing downstream signaling pathways, such
as the phosphatidylinositol-3-kinase/Akt and RAS/RAF/
MAP-activated protein kinase (MAPK) pathways.
The EGFR is overespressed in about 50-80% of CRCs
and has been the focus of a new drug development [5]
and antibodies targeting EGFR, such as cetuximab and
panitumumab, have been examined for therapeutic effi-
cacy in CRC patients [6].ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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of the EGFR, as induced by mutated KRAS or BRAF, is
important for the progression of colorectal cancer [7].
In human CRC, mutations in the KRAS gene have a
frequency of around 30%-40% and were linked to poor
outcomes, whereas mutations of the BRAF gene, a
downstream molecule of KRAS, occur in only 5%-10%
of patients with sporadic diseases. Mutations in the
KRAS and BRAF genes are frequently found to be mutu-
ally exclusive in colorectal cancer [8,9].
Recently, any activating mutations in the KRAS gene has
been proved to be predictor of response to epidermal
growth factor receptor-targeted therapies, such as cetuxi-
mab and panitumumab, for patients with metastatic colo-
rectal cancer [10].
Different somatic missense mutations in codons 12,
13, 61 and 146 are relevant for therapeutic efficacy of
anti-EGFR therapy [10-14]. In addition, among colorec-
tal tumors carrying wild-type KRAS, mutation of BRAF
or NRAS or PIK3CA or loss of PTEN expression may be
associated with resistance to EGFR-targeted monoclonal
antibody treatment, although these additional bio-
markers require further validation before incorporation
into clinical practice [15].
Activating mutations of these oncogenes are point
mutations (missense mutations) and they arise early
during the development of colorectal cancer [16]. The
activating mutations in KRAS oncogene are found
mostly in codons 12 and 13 (>90%) but also affect co-
dons 61 and 146 [12,13]. The most frequently observed
types of mutations are G > A transitions, G > T and
G > C transversions [17]. Identification of somatic-
activating mutations of BRAF has been reported in vari-
ous cancers, with by far the most common mutation
being a 1799 T > A transversion leading to a Val600Glu
(V600E) substitution [9].
Recent studies have demonstrated that a wild type
BRAF is also required for response to panitumumab or
cetuximab, suggesting that BRAF evaluation should be
used together with KRAS for selecting the patients who
could benefit from the anti-EGFR therapy [18,19].
In the present study, we detected mutations of KRAS
and BRAF proto-oncogenes in tumoral tissue specimens
in CRC patients of the Albanian population.
Correlations with various clinicopathological characteris-
tics of patients were further analyzed. To our knowledge,
we are the first to report the frequency and type of KRAS
and BRAF mutations in Albanian patients with advanced
CRC in order to introduce targeted therapy in the thera-
peutic modalities for management of this cancer in Albania.
Further researches are needed to determine how the
racial differences and etiological factors can influence
the spectrum and frequency of KRAS and BRAF muta-
tions between different populations.Methods
Patients and specimens
Tumor specimens used in this study were obtained from
159 CRC consecutive patients who underwent tumor re-
section at Tirana University Hospital during the period
2012–2013.
The study included 159 patients with histopathologic-
ally proven colorectal cancer; two pathologists independ-
ently confirmed the diagnosis.
Tumor stage was classified according to the Tumor,
Node and Metastases (TNM) classification of the Union
for International Cancer Control (UICC) staging.
The present study received the IRB approval from
University of Tirana (#12; 21/02/2014).
Histological examination
Tumors were classified as well-, moderately or poorly
differentiated adenocarcinoma in accordance with the
World Health Organization Classification (Jass JR, Sobin
LH. Histological typing of intestinal tumors. In World
Health Organization, ed. International Histological Clas-
sification of Tumors, 2nd edn. Berlin: Springer, 1989;
29–40). Mucinous tumors were separately classified.
Additional histological features such as necrosis,
tumor vascular invasion, stromal desmoplastic reaction
and infiltrative versus expansive pattern of growth, have
been evaluated but not considered as variable parame-
ters for statistical analysis.
DNA isolation
Sections (5 micron) were cut from paraffin-embedded
tumor tissue blocks and stained with haematoxylin &
eosin (H&E) for histopathological examination.
For DNA isolation, 5 sections, each of 4 micron thick-
ness, were used for each case. The H&E section was
used as a reference and tumor tissue was macrodissected
from the normal colonic epithelium and scraped off.
Genomic DNA was extracted from formalin-fixed
paraffin-embedded (FFPE) tissue samples using the
QIAamp DNA FFPE tissue kit (Qiagen) according to the
manufacturer’s recommendations and was amplied by
PCR at KRAS exon 2, 3 and 4 and BRAF exon 15.
Analysis of KRAS and BRAF mutations
Mutation analysis of KRAS codons 12, 13, 61, 146 and
BRAF codon 600 was carried out by direct sequencing
of amplified PCR products.
PCR was performed using 50 ng genomic DNA as
template. Each mixture contained 8 pmol of each pri-
mer. Primers were purchased from Roche Dagnostics
Spa, Monza, Italia.
The reactions were performed in 1X GeneAmp 10X
PCR Buffer II (Applied Biosystems), 0.25 μmol/L dNTPs,
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Polymerase (Applied Biosystems, CA USA).
The amplification reactions were as follows: an initial
denaturation cycle of 95°C for 5 min; 45 cycles of de-
naturation (95°C for 30 s), annealing (60°C for 30 s for
KRAS exon 2, 55°C for 30 s for KRAS exon 3, 4 and 57°C
for 30 s for BRAF exon 15), and elongation (72°C for
1 min); and a final extension cycle at 72°C for 5 min.
The PCR products were purified with 1 ml ExoI/SAP
(37°C for15 minutes, then 85°C for 15 minutes) and were
then sequenced directly on both strands using the BigDyeH
Terminator v1.1 cycle sequencing kit (Applied Biosystems)
according to manufacturer’s protocol and analysed by the
ABI 3500 Genetic Analyzer (Applied Biosystem, CA, USA).
Results
Of the 159 patients, 90 were male and 69 female; ranged
from 17 to 85 years of age (median 61.7). 24 patients
were stage I, 36 stage II, 84 stage III and 15 stage IV.
KRAS mutational status was tested in 159 clinical
samples of which 28 (17,6%) harboured at least one mu-
tation at codon 12, 13 or 146.
Specific nucleotide and codon changes detected are
listed in Table 1.
Mutations at codon 12 are the more frequent ones,
followed by codon 13 and 146 ones. No point mutation
was detected in KRAS at codon 61. 25 samples showed a
mutation at codon 12, 2 at codon 13 and 1 at codon 146.
The incidence of KRAS mutation was similar in men and
women. The predominant mutations were G >A transi-
tion while the most frequent mutation was G12D (8.1% of
all mutations). Representative electropherograms of KRAS
wild type and G12D are shown in Figure 1.
Of the 131 KRAS wild type samples, 10 (6,3%) har-
boured a mutation at codon 600 in exon 15 of BRAF
(V600E) (Table 2).Table 1 Frequency of Mutations in KRAS codon 12, 13, 61
and 146 (N = 159)
Nucleotide change Aminoacid change N. of mutated cases (%)
KRAS codon 12
c.35G > A p.G12D 13 (8.1)
c.34G > A p.G12S 1 (0.6)
c.35G > T p.G12V 4 (2.5)
c.34G > T p.G12C 4 (2.5)
c.35G > C p.G12A 3 (1.9)
KRAS codon 13




c.436G > A p.A146T 1 (0.6)Representative electropherograms of BRAF wild type
and with a V600E mutation are shown in Figure 2. In
addition, our data confirmed that mutations in KRAS
and BRAF are mutually exclusive.
All mutations found had previously been described to
be oncogenically active and were found in the COSMIC
(catalog of somatic mutations in cancer) database
(Sanger Institute, Cambridge, UK).
No association between KRAS and BRAF mutations
and various clinicopathological features such as age,
gender, tumor differentiation, UICC classification was
found (Table 3).
Discussion
The epidermal growth factor receptor (EGFR) plays a key
role in the development and progression of CRC. It trig-
gers a downstream signaling cascade such as RAS-RAF-
MAPK and PI3K-AKT pathway, which are involved in cell
proliferation, differentiation, survival and invasion. Among
the activating mutations downstream of EGFR, KRAS and
BRAF oncogenes participate in the MAPK pathway that
mediates cellular response to growth signals [20]. This
cascade is activated by the EGFR [21] that is overespressed
in 50-80% of colorectal tumors and therefore represent a
suitable target for the anticancer therapies with monoclo-
nal antibodies as cetuximab and paninutumab [22,23].
These molecules bind to the extracellular domain of EGFR
leading to the inhibition of its downstream signaling.
The anti-EGFR therapies have shown to be effective
only in a subset of patients with colorectal cancer [24].
To optimize the benefits and to reduce the risks of anti-
EGFR therapies, the EGFR, as well as the molecules in-
volved in its pathway, has been evaluated as potential
marker to predict the treatment outcomes. Recents stud-
ies have demonstrated that mutations in the KRAS gene
negatively predict the response to EGFR-targeted therap-
ies in patients with metastatic colorectal cancer [25,26].
The KRAS mutations that are responsible for the syn-
thesis of a permanently active KRAS protein [27,28] are
predominately identified in the 12 and 13 codon of the
gene [28]. Despite having a wild type KRAS, only 40-
60% of the patients will respond to treatment [29]. The
identification of the other important molecular determi-
nants of response is therefore of an outmost importance.
The BRAF-activating mutations have been reported in
various type of cancer: melanoma (70% of cases), thyroid
(30-70%), ovarian (15-30%) and colorectal cancer (5-
10%) [30,31]. All BRAF mutations occur within the kin-
ase domain resulting in an elevated kinase activity of the
BRAF protein. The p. Val600Glu (V600E) mutation is
the most common mutation in the BRAF gene, found in
approximately 80% of the cases [9,19]. Certain studies
have demonstrated that wild type BRAF is required for
response to panitumumab or cetuximab, suggesting that
Figure 1 Sequencing electropherogram of KRAS exon 2. (A) Wild-type. (B) G12D mutation.
Martinetti et al. Diagnostic Pathology 2014, 9:187 Page 4 of 7
http://www.diagnosticpathology.org/content/9/1/187BRAF should also be tested together with KRAS to select
the patients who are most likely to benefit from the anti-
EGFR therapy [19,32,33]. Our objective was the determine
the frequency of most common mutations in KRAS gene
(p.G12D, p.G12V, p.G12A, p.G12C, p.G12S, p.G12R, p.
G13D, p.Q61H, p.Q61L, p.Q61R, p.A146T, p.A146V, p.
A146P) together with the BRAF V600E mutation in
Albanian patients with metastatic colorectal cancer.
In our study, we have evaluated KRAS and BRAF mu-
tational status in 159 Albanian CRC patients using direct
sequencing. The present study is first to provide data on
frequency and type of KRAS and BRAF mutations of
colorectal cancer in Albanian population; no data is
present in the literature about this incidence.
In addition, we also tried correlate the presence of
KRAS and BRAF mutations at codon 12, 13, 61, 146 and
600 with various clinicopathological features such as age,
gender and grade as shown in Table 3.
In the present study, we did not find any significant
correlations between these molecular events and various
clinicopathological features, which may be partly attrib-
utable to the relatively small sample size.
In summary, our study reports that the incidence of
KRAS mutation in Albanian colorectal cancer patients isTable 2 Frequency of BRAF Mutations in Tumor Wild type
for KRAS codon 12, 13, 61 and 146 (N = 131)
Nucleotide change Aminoacid change No. of mutated cases (%)
BRAF codon 600
c.1799 > A p. V600E 10 (6.3%)less frequent when compared with the data from litera-
ture (35-50%) [14,34-37].
This is probably due to the different methodology since
we used direct sequencing and to small sample size.
Studies from various countries have analyzed the fre-
quency of the type of KRAS point mutation in CRC.
Most of the authors have identified the G > A transition
as the most frequently found type of KRAS mutation
[38,39]. In the current study, the G > A transition ap-
peared also to be the predominant mutation, followed by
G > T transversion. Among mutations in codons 12, the
substitution of glycine with aspartate has been reported
as the most frequent change. In accordance with our
data, previous studies have usually identified the glycine
to aspartate transition on codon 12 (p.G12D) as the
most frequent mutation of KRAS [40-48].
The percentage of BRAF mutation is similar to the
published data reporting the BRAF V600E mutation in
the range of 5 to 10% [19,49].
Although the mutations in KRAS are considered to be
a highly specific negative marker of response to cetuxi-
mab and panitumumab, the selection of patients for
anti-EGFR treatment on such basis is not sensitive
enough. Moreover, it has been reported that patients
with activating mutations in RAS, in addition to KRAS
exon 2, do not benefit from combined panitumumab
plus FOLFOX4 chemiotherapy [10].
Therefore, the BRAF mutational status is of utmost
importance to be verified as another molecular deter-
minant of response to anti-EGFR targeted monoclonal
antibody therapy.
Figure 2 Sequencing electropherogram of BRAF exon 15. (A) Wild-type. (B) V600E mutation.
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mutation in BRAF. These 10 patients represent 6.3% of
all tested patients.
All 10 patients with the V600E mutation in BRAF were
wild-type KRAS, and no BRAF mutations were found in
patients with a mutated KRAS genotype. This also is in
concordance with previously published observations byTable 3 Correlation between KRAS, BRAF mutations and
clinicopathological parameters in colorectal cancer (%)
Terms All Wild type KRAS Mutation BRAF Mutation
No.of patients 159 122 28 (17,6%) 10 (6,3%)
Median age 61,7
Gender
Male 90 69 18 (20%) 3 (3,3%)
Female 69 53 10 (14,5%) 7 (10,1%)
Differentiation
Poor 12 11 / 1 (8,3%)
Moderate 76 57 17 (22%) 3 (3,9%)
Mucinose 16 12 3 (18,7%) 1 (6,2%)
Well 52 39 8 (15,3%) 5 (9,6%)
UICC classification
I 24 17 5 (20,8) 2 (8,3%)
IIA 36 26 7 (19,4) 3 (8,3%)
IIIA 10 9 1 (10%) /
IIIB 70 55 11 (16%) 5 (7.1%)
IIIC 4 3 1 (25%) /
IV 15 12 3 (20%) /other authors that mutations in KRAS and BRAF are
mutually exclusive [8].Conclusions
In conclusion, we observed a frequency of 17,6% for mu-
tations in exon 2, 3 and 4 of the KRAS oncogene, pre-
dominantly in codon 12. The G > A transition and G > T
transversion were the most frequently observed muta-
tions, with the G > T transversion confined to codon 12.
Summing up the results about the KRAS and the
BRAF mutation carriers from our study, the portion of
potentially non-responsive patients for the anti-EGFR
treatment is 23,3%.
Thus, the anti-EGFR therapy could be beneficial for
the majority of Albanian population.
The results of this study indicate that the types of
KRAS mutations from CRC in Albania are similar to
other countries but with a lower frequency.
A limitation of this study is the absence of data on
NRAS mutations, considering that patients with RAS
mutations (KRAS or NRAS) do not respond to anti-
EGFR therapy.
These data should be confirmed on a larger study
group and in prospective studies in order to determine
whether these mutations contribute to progression of
CRC.Consent
Written informed consent was obtained from the pa-
tients for the publication of this study and any accom-
panying images.
Martinetti et al. Diagnostic Pathology 2014, 9:187 Page 6 of 7
http://www.diagnosticpathology.org/content/9/1/187Abbreviations
CRC: Colorectal cancer; EGFR: Epidermal growth factor receptor; TNM: Tumor,
node and metastases; UICC: Classification of the Union for International
Cancer Control staging; H&E: Haematoxylin & eosin; FFPE: Formalin-fixed
paraffin-embedded.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DM carried out the molecular studies and drafted the manuscript. RC carried
out the molecular studies. SK participated in the design of the study and
collected the samples. MA participated in the design of the study and
collected the samples. CC participated in the design of the study. VC
participated in the design of the study. MB participated in the design of the
study. LM conceived the study, participated in its design and drafted the
manuscript. All authors read and approved the final manuscript.
Acknowledgments
We would like to thank Giovanni Ferlito for his expert technical support.
Author details
1IOM Ricerca Srl, Catania, Italy. 2Morphopathology Laboratories, Tirana,
Albania. 3Department of Pathology, University of Tirana, Tirana, Albania.
4Department of Experimental Oncology, Mediterranean Institute of
Oncology, Via Penninazzo 7, 95029 Viagrande, Catania, Italy. 5Division of
Pathology, Centro di Riferimento Oncologico, Aviano, Italy. 6Department of
Clinical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
Received: 6 August 2014 Accepted: 7 September 2014
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010,
127:2893–2917.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007.
CA Cancer J Clin 2007, 57:43–66.
3. Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F:
The long and winding road to useful predictive factors for anti-EGFR
therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
Oncology 2009, 77(Suppl 1):57–68.
4. Vogelstein B, Fearon ER, Hamilton SR, Kem SE, Preisinger AC, Leppert M,
Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during
colorectal tumor development. Engl J Med 1998, 319(9):525–532.
5. Porebska I, Harlozińska A, Bojarowski T: Expression of the tyrosine kinase
activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal
adenocarcinomas and adenomas. Tumour Biol 2000, 21(2):105–115.
6. Reynolds NA, Wagstaff AJ: Cetuximab: in the treatment of metastatic
colorectal cancer. Drugs 2004, 64(1):109–118.
7. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M,
Veronese S, Siena S, Bardelli A: Oncogenic activation of the RAS/RAF
signaling pathway impairs theresponse of metastatic colorectal cancers
to anti-epidermal growth factor receptor antibody therapies. Cancer Res
2007, 67(6):2643–2648.
8. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE:
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature
2002, 418(6901):934.
9. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J,
Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y,
Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C,
Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA,
Cooper C, Shipley J, et al: Mutations of the BRAF gene in human cancer.
Nature 2002, 417(6892):949–954.
10. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y,
Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-
Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J,
Sidhu R, Patterson SD: Panitumumab-FOLFOX4 treatment and RAS
mutations in colorectal cancer. N Engl J Med 2013, 369(11):1023–1034.11. Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N: Prognostic and
predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and
TP53CRC collaborative studies. Ann Oncol 2005, 16(Suppl 4):iv44–iv49.
12. Edkins S, O’Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C,
Davies H, Dalgliesh G, Forbes S, Hunter C, Smith R, Stephens P, Goldstraw P,
Nicholson A, Chan TL, Velculescu VE, Yuen ST, Leung SY, Stratton MR,
Futreal PA: Recurrent KRAS codon 146 mutations in human
colorectalcancer. Cancer Biol Ther 2006, 5(8):928–932.
13. Oliveira C, Westra JL, Arango D, Ollikainen M, Domingo E, Ferreira A,
Velho S, Niessen R, Lagerstedt K, Alhopuro P, Laiho P, Veiga I, Teixeira MR,
Ligtenberg M, Kleibeuker JH, Sijmons RH, Plukker JT, Imai K, Lage P, Hamelin R,
Albuquerque C, Schwartz S Jr, Lindblom A, Peltomaki P, Yamamoto H,
Aaltonen LA, Seruca R, Hofstra RM: Distinct patterns of KRAS mutations
incolorectal carcinomas according to germline mismatch repair defects and
hMLH1 methylation status. Hum Mol Genet 2004, 13(19):2303–2311.
14. Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R,
Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA,
Chan AT, Fuchs CS, Ogino S: Analyses of clinicopathological, molecular,
and prognostic associations of KRAS codon 61 and codon 146
mutations in colorectal cancer: cohort study and literature review.
Mol Cancer 2014, 13:135.
15. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A:
Biomarkers predicting clinical outcome of epidermal growth factor
receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer
Inst 2009, 101(19):1308–1324.
16. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen
A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J,
Markowitz SD: Comparative lesion sequencing provides insights into
tumor evolution. Proc Natl Acad Sci U S A 2008, 105(11):4283–4288.
17. Risio M, Malacarne D, Giaretti W: KRAS transitions and villous growth in
colorectal adenomas. Cell Oncol 2005, 27(5–6):363–366.
18. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC,
Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer
C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med 2008, 359(17):1757–1765.
19. Di Nicolantonio F1, Martini M, Molinari F, Sartore-Bianchi A, Arena S,
Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A: Wild
Type BRAF is required for response to panitumumab or cetuximab in
metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705–5712.
20. Peyssonnaux C, Eychene A: The Raf/MEK//ERK pathway: new concepts of
activation. Biol Cell 2001, 93(1–2):53–62.
21. Harari PM, Allen GW, Bonner JA: Biology of interactions: anti-epidermal
growth factor receptor agents. J Clin Oncol 2007, 25(26):4057–4065.
22. Hemming AW, Davis NL, Kluftinger A, Robinson B, Quenville NF, Liseman B,
LeRiche J: Prognostic markers of colorectal cancer: an evaluation of DNA
content, epidermal growth factor receptor, and ki-67. J Surg Oncol 1992,
51(3):147–152.
23. Bonomi PD, Buckingham L, Coon J: Selecting patients for treatment with
epidermal growth factor tyrosine kinase inhibitors. Clin Cancer Res 2007,
13(15Pt2):s4606–s4612.
24. Dassonville O, Bozec A, Fischel JL, Milano G: EGFR targeting therapies:
monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and
differences. Crit Rev Oncol Hematol 2007, 62(1):53–61.
25. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T,
Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is
required for panitumumab efficacy in patients with metastatic colorectal
cancer. J Clin Oncol 2008, 26(10):1626–1634.
26. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G,
Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y,
Van Cutsem E, Tejpar S: KRAS wild-type state predicts survival and is
associated to early radiological response in metastatic colorectal cancer
treated with cetuximab. Ann Oncol 2008, 19(3):508–515.
27. Zenker M, Lehmann K, Schulz AL: Expansion of the genotypic and
phenotypic spectrum in patients with KRAS germline mutations. J Med
Genet 2007, 44(2):131–135.
28. Van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P,
Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G,
Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A: KRAS mutation
testing for predicting response to anti-EGFR therapy for colorectal
carcinoma proposal for an European quality assurance program.
Virchows Arch 2008, 453(5):417–431.
Martinetti et al. Diagnostic Pathology 2014, 9:187 Page 7 of 7
http://www.diagnosticpathology.org/content/9/1/18729. Linardou H1, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P,
Papadimitriou CA, Murray S: Assessment of somatic k-RAS mutations as a
mechanism associated with resistance to EGFR-targeted agents: a
systematic review and meta-analysis of studies in advanced non-small-cell
lung cancer and metastatic colorectal cancer. Lancet Oncol 2008,
9(10):962–972.
30. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, Gambacorti-Passerini C:
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032
leads to different responses in melanoma and thyroid carcinoma cells.
Mol Cancer Res 2008, 6(5):751–759.
31. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S,
Hemminki K: BRAF mutations in metastatic melanoma: a possible
association with clinical outcome. Clin Cancer Res 2003, 9(9):3362–3368.
32. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G,
Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V,
Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F: KRAS
codon 61, 146 and BRAF mutations predict resistance to cetuximab plus
irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal
cancer. Br J Cancer 2009, 101(4):715–721.
33. Laurent-Puig P, Cayre A, Manceau G: Analysis of PTEN, BRAF, and EGFR
status in determining benefit from cetuximab therapy in wild-type KRAS
metastatic colon cancer. J Clin Oncol 2009, 27(35):5924–5930.
34. Ozen F, Ozdemir S, Zemheri E, Hacimuto G, Silan F, Ozdemir O: The
protoncogene KRAS and BRAF profiles and some clinical charateristics in
colonrectal cancer in the Turkish population. Genet Test Mol Biomarkers
2013, 17(2):135–139.
35. Rako I, J. Jakic-Razumovic J, Katalinic D, Sertic J, Plestina S: Mutation pattern
of KRAS and BRAF oncogenes in colorectal cancer patients. Neoplasma
2012, 59(4):376–383.
36. Bozzao C, Varvara D, Piglionica M, Bagnulo R, Forte G, Patruno M, Russo S,
Piscitelli D, Stella A, Resta N: Survey of KRAS, BRAF and PIK3CA mutational
status in 209 consecutive Italian colorectal cancer patients. Int J Biol
Markers 2012, 27(4):e366–e374.
37. Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS: Frequency of
KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes
Chromosomes Cancer 2011, 50(5):307–312.
38. Topal MD: DNA repair, oncogenes and carcinogenesis. Carcinogenesis
1998, 9(5):691–696.
39. Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barbacid M: Direct
mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N- methylurea
during initiation of mammary carcinogenesis in rats. Nature 1985,
315(6018):382–385.
40. Adams R, Meade A, Wasan H, Griffiths G, Maughan T: Cetuximab therapy
in first-line metastatic colorectal cancer and intermittent palliative
chemotherapy: review of the COIN trial. Expert Rev Anticancer Ther 2008,
8:1237–1245.
41. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA: Kirsten ras
mutations in patients with colorectal cancer: the multicenter “RASCAL”
study. J Natl Cancer Inst 1998, 90(9):675–684.
42. Barault L1, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lièvre A,
Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P, Piard F:
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase)
signaling network correlate with poor survival in a population-based
series of colon cancers. Int J Cancer 2008, 122(10):2255–2259.
43. Cerottini JP, Caplin S, Saraga E, Givel JC, Benhattar J: The type of K-ras
mutation determines prognosis in colorectal cancer. Am J Surg 1998,
175(3):198–202.
44. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, Bastit
L, Killian A, Sesboüé R, Tuech JJ, Queuniet AM, Paillot B, Sabourin JC, Michot
F, Michel P, Frebourg T: Clinical relevance of KRAS mutation detection in
metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
Br J Cancer 2007, 96(8):1166–1169.
45. Kressner U1, Bjørheim J, Westring S, Wahlberg SS, Påhlman L, Glimelius B,
Lindmark G, Lindblom A, Børresen-Dale AL: Ki-ras mutations and prognosis
in colorectal cancer. Eur J Cancer 1998, 34(4):518–521.
46. Moerkerk P, Arends JW, Van Driel M, De Bruine A, De Goeij A, Ten Kate J:
Type and number of Ki-ras point mutations relate to stage of human
colorectal cancer. Cancer Res 1994, 54(13):3376–3378.
47. Span M, Moerkerk PT, De Goeij AF, Arends JW: A detailed analysis of K-ras
point mutations in relation to tumor progression and survival in
colorectal cancer patients. Int J Cancer 1996, 69(3):241–245.48. Urosevic N, Krtolica K, Skaro-Milic A, Knezevic-Usaj S, Dujic A: Prevalence
of G-to-T transversions among K-ras oncogene mutations in human
colorectal tumors in Yugoslavia. Int J Cancer 1993, 54(2):249–254.
49. Yuen ST, Davies H, Chan TL, Ho JW, Bignell GR, Cox C, Stephens P, Edkins S,
Tsui WW, Chan AS, Futreal PA, Stratton MR, Wooster R, Leung SY: Similarity
of the phenotypic patterns associated with BRAF and KRAS mutations in
colorectal neoplasia. Cancer Res 2002, 62(22):6451–6455.
doi:10.1186/s13000-014-0187-7
Cite this article as: Martinetti et al.: KRAS and BRAF mutational status in
colon cancer from Albanian patients. Diagnostic Pathology 2014 9:187.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
